On Friday, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s shares declined -3.30% to $200.99.
Alexion Pharmaceuticals, Inc. (ALXN) declared that the Company will report its financial results for the second quarter ended June 30, 2015 on Thursday, July 30, 2015 before the US financial markets open. Following the release of the financial results, Alexion administration will conduct a conference call and audio webcast on Thursday, July 30, 2015, at 10:00 a.m. Eastern Time (ET).
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
Acacia Research Corp (NASDAQ:ACTG)’s shares dropped -0.64% to $9.38.
Acacia Research Corporation (1) ( ACTG) stated results for the three months ended June 30, 2015.
- Revenues for the second quarter of 2015 were $40,336,000, as contrast to $50,076,000 in the comparable preceding year quarter.
- Revenues for the six months ended June 30, 2015 were $74,546,000, as contrast to $62,654,000 in the comparable preceding year period.
- GAAP net loss for the second quarter of 2015 was $3,686,000, or $0.08 per diluted share, as contrast to $12,949,000, or $0.27 per diluted share for the comparable preceding year quarter.
- Non-GAAP net income for the second quarter of 2015 was $12,719,000, or $0.25 per diluted share, as contrast to $7,886,000, or $0.16 per diluted share for the comparable preceding year quarter. See below for information regarding non-GAAP measures.
- Cash and cash equivalents, restricted cash and investments totaled $166,892,000 as of June 30, 2015.
Acacia Research Corporation, through its auxiliaries, invests in, develops, licenses, and enforces patented technologies in the United States. It assists patent owners with the prosecution and development of their patent portfolios; the protection of their patented inventions from unauthorized use; the generation of licensing revenue from users of their patented technologies; and enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation.
At the end of Friday’s trade, First Solar, Inc. (NASDAQ:FSLR)‘s shares surged 0.54% to $42.97.
First Solar, Inc. (FSLR) declared that it has signed an agreement to supply its high performance photovoltaic (PV) modules to power the 200 megawatt (MW)AC second phase of the Mohammed bin Rashid Al Maktoum Solar Park in Dubai, the United Arab Emirates.
Earlier this year, a consortium led by ACWA Power, a leading water and power developer, owner and operator based in Saudi Arabia, and TSK, a Spanish engineering and construction company, was selected by the Dubai Electricity and Water Authority (DEWA) to develop, construct, own and operate the independent power project. According to the consortium, the project’s tariff of 5.84 USD cents per kilowatt-hour establishes a new global benchmark, reducing the cost of solar electricity by over 20 percent.
First Solar, Inc. provides solar energy solutions worldwide. The company operates through two segments, Components and Systems. The Components segment designs, manufactures, and sells solar modules that convert sunlight into electricity. This segment manufactures cadmium telluride and crystalline silicon modules for project developers and system integrators, in addition to owners and operators of photovoltaic (PV) solar power systems.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ended its Friday’s trading session with 7.06% gain, and closed at $9.25.
Progenics Pharmaceuticals, Inc., (PGNX), an oncology company developing innovative ways to target and treat cancer, declared recently that it will host a conference call and webcast to review second quarter 2015 financial results on Thursday, August 6, at 8:30 a.m. ET.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.